Muscarinic agonists

Details Muscarinic agonists Muscarinic agonists

2006-05-03

2009-08-18

Coleman, Brenda L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S314000, C546S157000, C546S158000, C546S165000, C546S176000

Reexamination Certificate

active

07576100

ABSTRACT:
The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.

REFERENCES:
patent: 3324137 (1967-06-01), Zenitz
patent: 3365457 (1968-01-01), Zenitz
patent: 5707798 (1998-01-01), Brann
patent: 5770734 (1998-06-01), Sabb
patent: 5786367 (1998-07-01), Oshiro et al.
patent: 2004/0067931 (2004-04-01), Kelly et al.
patent: 2005/0130961 (2005-06-01), Davis et al.
patent: 0 541 263 (1993-05-01), None
patent: 0 577 325 (1994-01-01), None
patent: 0 584 487 (1994-03-01), None
patent: 0 934 932 (1999-08-01), None
patent: 1 260 512 (2002-11-01), None
patent: WO 99 50247 (1999-10-01), None
patent: WO 01 27104 (2001-04-01), None
patent: WO 01/49679 (2001-07-01), None
patent: WO 01 83472 (2001-11-01), None
patent: WO 03/057672 (2003-07-01), None
Messer W., The Utility of Muscarinic Agonists in the Treatment of Alzheimer's Disease, Journal of Molecular Neuroscience, vol. 19, pp. 187-193, 2002.
International Search Report for PCT Application No. PCT/US02/41617 mailed Aug. 25, 2003.
International Search Report and Written Opinion from International Application No. PCT/US2005/045313 dated May 23, 2006.
Bodick et al., Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease, Arch. Neurol. 54:465-473 (1997).
Bond et al., Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β2-adrenoceptor, Nature 374:272 (1995).
Brauner-Osborne, et al. Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): high throughput assays in mammalian cells, Eur. J. Pharmacol. 295:93-102 (1996).
Bymaster et al., Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R, 6R)6-(3-propylthio-1,2,5-thiadiazol-4-y1)-1-azabicyclo[3.2.1]octane, Eur. J. Pharmacol. 356:109-119 (1998).
Bymaster et al., Potential role of muscarinic receptors in schizophrenia, Life Sci. 64:527-534 (1999).
Felder et al., Therapeutic opportunities for muscarinic receptors in the central nervous system, J. Med. Chem. 43:4333-4353 (2000).
Friedman et al., Pharmacologic strategies for augmenting cognitive performance in schizophrenia, Biol. Psychiatry 45:1-16 (1999).
Mokrosz et al., 5-HT1A and 5HT2A receptor affinity and functional profiles of some N-[3-(4-aryl-1-piperazinyl)propyl] derivatives of indolin-2(1H)-one, quinolin-2(1H)-one and isoquinolin-1(2H)-one, Pharmazie, 52, 6:423-428 (1997).
Pace et al., A mutant α subunit of Gl2 induces neoplastic transformation of Rat-1 cells, Proc. Natl. Acad. Sci. USA 88:7031-35 (1991).
Rowley et al., Current and novel approaches to the drug treatment of schizophrenia, J. Med. Chem. 44:477-501 (2001).
Sauerberg et al., Muscarinic agonists with antiphsychotic-like activity: structure-activity relationships of 1,2,5-Thiadiazole analogues with functional dopamine antagonist activity, J. Med. Chem. 41:4378-4384 (1998).
Shannon et al., Xanomeline: a novel muscarinic receptor agonist with functional selectivity for m1 receptors, J. Pharmacol. Exp. Ther. 269:271-281 (1994).
Shannon et al., Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats, J. Pharmacol. Exp. Ther. 290:901-907 (1999).
Shannon et al., Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice, Schizophrenia Res. 42:249-259 (2000).
Spalding T.A., Trotter C., Skjaerbaek N., Messier T.L., Currier E.A., Burstein E.S., Li D., Hacksell U., Brann M.R, Discovery of an ectopic activation site on the M1 muscarinic receptor, Mol. Pharmacol. 61(6):1297-302 (2002).
Vallar et al., Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas, Nature 330:556-58 (1987).

Affiliated with

Also associated with

Rating

Muscarinic agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Muscarinic agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Muscarinic agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4121473